Compare JVA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | CTXR |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 18.9M |
| IPO Year | 1997 | 2010 |
| Metric | JVA | CTXR |
|---|---|---|
| Price | $3.41 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 89.7K | ★ 239.6K |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $0.48 |
| 52 Week High | $5.62 | $2.24 |
| Indicator | JVA | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 47.28 |
| Support Level | $3.28 | $0.55 |
| Resistance Level | $3.92 | $0.60 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 18.11 | 44.43 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.